WEED:CA:TSX-Canopy Growth Corp (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 3.85

Change

-0.28 (-6.78)%

Market Cap

CAD 0.60B

Volume

1.97M

Analyst Target

CAD 23.02
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.01 (-0.09%)

CAD 3.94B
TLRY:CA Tilray Inc

-0.12 (-5.69%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

-0.17 (-7.42%)

CAD 1.61B
CRON:CA Cronos Group Inc

+0.01 (+0.35%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

-0.33 (-2.64%)

CAD 0.75B
AOV:CA Amotiv Limited

+0.01 (+0.18%)

CAD 0.58B
GUD:CA Knight Therapeutics Inc.

+0.01 (+0.18%)

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

+0.25 (+3.03%)

CAD 0.54B
CPH:CA Cipher Pharmaceuticals Inc

+0.08 (+0.55%)

CAD 0.38B
ACB:CA Aurora Cannabis Inc

-0.29 (-4.34%)

CAD 0.36B

ETFs Containing WEED:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.28% 23% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.28% 23% F 8% B-
Trailing 12 Months  
Capital Gain -36.99% 19% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.99% 19% F 4% F
Trailing 5 Years  
Capital Gain -98.56% 14% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.56% 14% F N/A F
Average Annual (5 Year Horizon)  
Capital Gain 76.08% 91% A- 96% N/A
Dividend Return 76.08% 91% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 751.73% 9% A- 2% F
Risk Adjusted Return 10.12% 73% C 27% F
Market Capitalization 0.60B 78% C+ 61% D-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector